Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: RLYB

Rallybio Corporation

Healthcare | Biotechnology

No licensed closing price on file for RLYB. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-1.59

Rallybio Corporation (NASDAQ: RLYB) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 04:34 UTC.

What Rallybio Corporation does

Rallybio is a clinical-stage biotechnology company led by experienced industry professionals focused on developing therapies for severe and rare diseases. The company's lead program, RLYB116, is a C5 inhibitor designed to treat diseases caused by complement dysregulation, and it has an additional program, RLYB332, a matriptase-2 antibody in preclinical development for iron overload diseases. Rallybio has agreed to merge with Candid, a clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune diseases, with concurrent funding from investors.

Summarized from Rallybio Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-1.59

Revenue, margins & earnings

FY2024: net loss $58M on revenue $636,000$636,000FY2024FY2025: net loss $9M on revenue $858,000$858,000FY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-14
  • 2026-10-14DirectorOption exercise3,562$8.5K
  • 2026-10-14DirectorOption (Right to Buy)Option exercise-2,062—
  • 2026-10-14DirectorOption exercise2,062$31.5K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Rallybio Corporation do?

Rallybio is a clinical-stage biotechnology company led by experienced industry professionals focused on developing therapies for severe and rare diseases.

When did RLYB last file with the SEC?

Rallybio Corporation's most recent SEC filing on record is a 8-K filed 2026-06-01. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 04:34 UTC. This page is also available as JSON at /api/data?ticker=RLYB and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for RLYB and 5,000+ tickers.

Create a free account — keep RLYB
For your agent
GET /api/data?ticker=RLYB

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt